Mr. Speaker, Health Canada is committed to providing access to safe and effective therapeutic products, including products to meet the needs of patients with rare diseases.
Spinraza was reviewed as a priority and approved for treatment for patients with spinal muscular atrophy in the summer of 2017. As with all medications, the responsibility for decisions regarding funding and reimbursement lies primarily with provinces and territories.